Effects of Resistance Exercise and Whey Protein Supplementation on Irisin Levels in Patients with MASLD Under a Calorie-Restricted Diet
Nutrients · 2026
DOI: 10.3390/nu18081272 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2026. Verfasst von Feng-Rui Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sport Science, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: Fibronectins, Whey Proteins, Caloric Restriction, Resistance Training. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Objectives
The aim of this study was to explore the combined effects of resistance exercise and whey protein supplementation on plasma irisin levels in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) under a 30% calorie-restricted weight loss diet.
Methods
Thirty adult patients with MASLD were randomized into the following three groups for a 4-week intervention: calorie restriction group (CR) (n = 8), CR with resistance exercise group (EX) (n = 11), and CR with resistance exercise and whey protein group (EX + P) (n = 11; 0.7 g/kg per day). All participants received boxed meals providing 70% of their total energy expenditure. The participants in the resistance exercise groups performed full-body resistance exercises 5 days/week (50–75% one-repetition maximum). Plasma irisin level, controlled attenuation parameter (CAP), and body composition were assessed before and after the intervention.
Results
Plasma irisin levels significantly increased in the EX (+2.24 ng/mL, p = 0.016) and EX + P (+4.86 ng/mL, p = 0.004) groups but not in the CR group. Muscle mass increased significantly only in the EX + P group. The CAP decreased in all groups. The change in irisin level was negatively correlated with the change in CAP (r = −0.459, p = 0.032).
Conclusions
Resistance exercise under calorie-restricted conditions effectively increased plasma irisin levels in patients with MASLD, whereas caloric restriction alone did not. Furthermore, a stronger increasing trend in the plasma irisin levels was observed with whey protein supplementation. An increase in irisin levels was significantly associated with hepatic fat reduction, suggesting that irisin may serve as a biomarker reflecting improvements in hepatic steatosis following lifestyle intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sport Science, Pusan National University, Busan 46241, Republic of Korea.
- Research Institute of Human Ecology, Pusan National University, Busan 46241, Republic of Korea.
- Department of Kinesiology and Sport Management, Texas Tech University, Lubbock, TX 79409, USA.
- Gastroenterology, Soon Chun Hyang University Cheonan Hospital, Cheonan 31151, Republic of Korea.
ORCID-Profile: Feng-Rui Zhang, Chae-Been Kim, Dohyun Ahn, Hae-Ri Heo, Eun-Ah Jo, Jung-Jun Park
Förderung
- National Research Foundation of Korea
Zitieren
APA
Zhang, F. R., Kim, C. B., Ahn, D., Sung, J., Oh, J. H., Heo, H. R., Jo, E. A., Kim, H. S., & Park, J. J. (2026). Effects of Resistance Exercise and Whey Protein Supplementation on Irisin Levels in Patients with MASLD Under a Calorie-Restricted Diet. Nutrients. https://doi.org/10.3390/nu18081272
Vancouver
Zhang FR, Kim CB, Ahn D, Sung J, Oh JH, Heo HR, et al. Effects of Resistance Exercise and Whey Protein Supplementation on Irisin Levels in Patients with MASLD Under a Calorie-Restricted Diet. Nutrients. 2026. doi:10.3390/nu18081272
BibTeX
@article{Zhang2026,
author = {Zhang, Feng-Rui and Kim, Chae-Been and Ahn, Dohyun and Sung, Jinwoo and Oh, Ju-Hwan and Heo, Hae-Ri and Jo, Eun-Ah and Kim, Hong-Soo and Park, Jung-Jun},
title = {Effects of Resistance Exercise and Whey Protein Supplementation on Irisin Levels in Patients with MASLD Under a Calorie-Restricted Diet},
journal = {Nutrients},
year = {2026},
doi = {10.3390/nu18081272}
}
EUVIMED